Conference Programme
  • Date
  •         
  • Category
  • Theme
  • CPHI Japan
    Pharma IT
  • Keyword
0Lectures are applicable
6K-01
April 9(Wed.)
9:15-10:15
Simultaneous interpretation

Regulatory effort to eliminate Drug-Lag/Drug-Loss problem and to ensure stable supply of pharmaceuticals

 

※Opening Ceremony will be held from 9:15am

Mr. Katsuaki Ura 
Director, Advanced Therapeutics Evaluation Office 
Pharmaceutical Evaluation Division, Pharmaceutical Safety Bureau
Ministry of Health, Labour and Welfare (MHLW)


In recent years, with the changing environment surrounding the pharmaceutical industry, various problems have been pointed out, such as the occurrence of drug lag/loss and concerns about stable supply. To address such problems, we have improved the operation of lots of regulatory systems based on the discussion on “Study Group on Pharmaceutical Regulations for Strengthening Drug Discovery and Ensuring Stable Supply”, and also proceed with the procedures to revise the Act on Ensuring Quality, Efficacy and Safety of Pharmaceuticals, Medical Devices, etc.

FREE

Register
6K-02
April 9(Wed.)
11:00-12:00
Mr. TOMOMI Kawamata

The industrial structure of generic drugs

Mr. TOMOMI Kawamata


President  
NISSIN Pharmaceutical co.,LTD


President 
Japan Generic Medicines Association


Although the market for generic drugs has expanded significantly as a result of government measures to promote their use, there is little prospect for significant market expansion in the future, although the government is on track to achieve its goals. Furthermore, the profitability of generic drugs has been declining significantly due to the lower NHI drug price ratio at the time of their initial listing on the market and the annual NHI price revisions. In response to this market environment, we would like to discuss the problems of the industry structure in the future.

FREE

Register
6K-03
April 9(Wed.)
13:00-14:00
Simultaneous interpretation
Mr. Toshihiko  Miyajima

Japan's universal health care system and pharmaceutical industry in Japan

Mr. Toshihiko  Miyajima
Director General 
The Federation of Pharmaceutical Manufacturer's Association of Japan


My lecture outlins Japan's universal health care system and discusses the role that pharmaceutical play in it.In addition,I will describe the current situation of the pharmaceutical industry in Japan and recent trends in pharmaceutical policy.Based on these findings,I will present the direction that the pharmaceutical industry in Japan should aim for in the future.

FREE

Register
6K-05
April 9(Wed.)
14:30-16:00
Mr. Satoshi Shiratori

Japan Active Pharmaceutical Ingredient Association (JAPIA)

Factory manager/management meeting

-Daily issues in the operation of active pharmaceutical ingredients plants-

Mr. Satoshi Shiratori  (moderator) 
President &CEO 
SHIRATORI Pharmacal Co.,Ltd.


A panel discussion will be held in which plant managers and managers of member companies of the JAPIA will introduce changes and challenges in the business environment, fostering a quality culture, the impact of the supply chain and responses, and safety education initiatives.

The discussion will be moderated by Mr. Satoru Shiratori,

President of Shiratori Pharmaceutical Co.,Ltd.

FREE

Register
6A-01
April 9(Wed.)
10:15-11:15
Mr. Katsuhiko Miwa
Mr. Shinichiro Fuse
Mr. Shio Komiya
Mr. Hirotaka Shinohara

Obtaining high-purity peptides is difficult – That's no surprise

Mr. Katsuhiko Miwa
President and CEO
ChromaJean Co., Ltd.

 

Mr. Shinichiro Fuse
Professor
Graduate School of Pharmaceutical Sciences
Nagoya University

 

Mr. Shio Komiya
Manufacturing Technology Development Professional for Middle Molecule APIs
API Process Development Department, Chemical Process
Chugai Pharmaceutical, Co., Ltd.

 

Mr. Hirotaka Shinohara
Deputy Manager
Production Technology
COSMO BIO Co.,LTD.


Obtaining peptides with high purity, which are attracting attention as next-generation drugs is considerably more difficult than small molecules. Everyone's heart is broken. We devised a plan to discuss this problem with players with different expertise and different approaches. Where will the efforts to bring together "upstream" and "downstream" technologies end up? In this seminar, professionals in organic synthesis or separation science will collude to break into "animal trail".

FREE

Register
6A-03
April 9(Wed.)
13:00-13:45
Mr. Katsuhiko Matsumoto

Whole-organ analysis using tissue-clearing technique CUBIC


CUBIC is a tissue-clearing technique that uses safe, water-based reagents, enabling whole-organ transparency while preserving the fluorescence of proteins such as GFP. Cleared organs can undergo immunostaining and be imaged with light-sheet microscopy to obtain 3D datasets at single-cell resolution. This presentation will detail the methodology for whole-organ analysis using CUBIC and its applications in drug discovery.

FREE

Register
6A-04
April 9(Wed.)
14:15-15:00
Mr. Naoki Nishimoto

Cheers to challengers aiming for innovation from pharmaceutical manufacturing DX

Mr. Naoki Nishimoto
Products Lifescience practice 
Associate Director 
Accenture Japan Ltd,


At the frontline manufacturing sites, we are striving to deliver as many high-quality medicines as possible to patients, using “Kaizen” as a lever.

In addition, "manufacturing/factory DX" has been attracting attention recently, and it has overcome the GMP barrier and is gradually starting to see results.

On the other hand, we often hear people asking, "How do I actually do it?" "What's so great about DX?"

In this session, we will delve into the essence of DX, which we cannot hear about anymore, and explain how to utilize it in daily "kaizen".

FREE

Register
6A-05
April 9(Wed.)
15:30-16:15
Mr. Naoki Shida

Development electrosynthesis processes using solid polymer electrolyte electrolysis technology

Mr. Naoki Shida
Associate Professor
Department of Chemistry and Life Science
Yokohama National University


Organic electrolysis is attracting attention as a means of achieving sustainable chemical production. Among these, solid-polymer electrolyte (SPE) electrolysis technology is attracting attention because it does not require electrolytes in solution and boasts a high energy conversion efficiency. In this presentation, we will introduce our recent results on organic electrolysis synthesis based on SPE electrolysis technology.

FREE

Register
5A-01
April 9(Wed.)
10:15-11:15
Mr. Keita Komatsu

Policy Directions for the Promotion of Biopharmaceuticals and Regenerative Medicine Industry

Mr. Keita Komatsu
Principal Deputy Director
Bio-Industry Division
Ministry of Economy, Trade and Industry


The market for biopharmaceuticals and regenerative medicine products has been rapidly expanding in recent years. To support the industry in Japan, the Ministry of Economy, Trade and Industry (METI) is promoting start-up companies, establishing manufacturing facilities, and developing manufacturing technologies. This presentation will offer a detailed explanation of these initiatives and their background, as well as discuss recent changes in the market environment and future policy directions.

FREE

Register
5A-02
April 9(Wed.)
11:30-12:15
Simultaneous interpretation
Mr. HoUng Kim

The strategy and positioning in Japan of global company specializing in  antibody biopharma

 

*Japanese-English AI real-time translation subtitles available.
Attendees must provide their own smartphones and earphones.

Mr. HoUng Kim
President and Representative Director,
CELLTRION HEALTHCARE Japan K.K 


Cooperate Executive Vice president
Head of JAL (Japan, Asia, Laten America) division,
CELLTRION INC.


FREE

Register
5A-03
April 9(Wed.)
12:50-13:30

FREE

Register
5A-04
April 9(Wed.)
13:50-14:20
Mr. Kazuhiro Takumi

How Forge Biologics is improving the accessibility of genetic medicines through better manufacturing

Mr. Kazuhiro Takumi
VP, Global Coordination Officer
Forge Biologics Inc.


Forge Biologics has built a company focused on providing end-to-end manufacturing services for Recombinant adeno-associated virus (rAAV) gene therapies utilizing a transient plasmid transfection process. In this seminar, we will describe how Forge is improving the accessibility of genetic medicines through better manufacturing by making molecular improvements, process improvements, building enhanced analytics, scaling up our reactors and purification systems, scaling out our facility to increase the number of cGMP suites, and providing integrated regulatory support. In 2023, Forge joined Ajinomoto Group, a global business investing in our long-term growth and vision of providing hope to patients suffering from genetic diseases.

FREE

Register
5A-05
April 9(Wed.)
14:40-15:10
Hiroaki Hamana, Ph.D
Mr. Koji Nakamura

The latest trend and some case studies on the development of the downstream processes for the wide variety of biologics

Hiroaki Hamana, Ph.D
Senior Specialist
Life Science, Process Chromatography Unit
Bio-Rad Laboratories

 

Mr. Koji Nakamura
Manager
Life Science, Process Chromatography Unit
Bio-Rad Laboratories


According to the diversification of biopharmaceutic modalities in recent years, the market expectations for new chromatography technologies in downstream development are increasing day by day.

In this seminar, we will propose our solutions for biopharmaceutic purification, including introduction of Bio-Rad's chromatography media family and most newly developed mixed-mode resin.

FREE

Register
5A-06
April 9(Wed.)
15:30-16:00
Mr. Yoshinori Kanazawa
Mr. Toshikazu Kobayashi

Optimization of Biopharmaceutical Lab Operations: Utilizing Asset Performance Management and OPC UA

Mr. Yoshinori Kanazawa
SSD Enterprise Service Sales
Agilent Technologies

 

Mr. Toshikazu Kobayashi
Sales Manager
Pharmaceutical Sales Department
Agilent Technologies


In this seminar, we will introduce methods to simplify, optimize, and transform biopharmaceutical lab operations using Agilent Asset Performance Management and OPC UA automation to reduce ancillary tasks and focus on core activities.

FREE

Register
5A-07
April 9(Wed.)
16:20-16:50

Development of a novel nucleic acid medicine technology, Staple oligomer, capable of regulating protein expression levels

Mr. Kiyoshi Tanigawa
CEO & Co-Founder
StapleBio Inc.


Staple oligomer is a next-generation nucleic acid medicine technology that induce artificial G-quadruplex (G4) formation by specifically hybridizing to target mRNAs. This unique feature allows it to 'downregulate ' or 'upregulate ' protein expression levels according to therapeutic goals. Importantly, these effects are highly selective to the target gene, ensuring the safety and precision of the treatment. In this session, we will introduce an overview of Staple oligomer technology and its potential application in the treatment of rare diseases.

FREE

Register
C5-01
April 9(Wed.)
10:45-11:15

Innovations in Biologics Toward 2025: Technological Trends and Market Outlook

Ms. Shiho Yoshitomi
Solution Consultant、APAC
Evaluate


Our company collects and analyzes a wide range of data related to the pharmaceutical industry, providing essential insights for pharmaceutical companies and their manufacturing partners, CDMO firms, to make informed decisions regarding development and business strategies. In this seminar, we will present case studies analyzing trends in new drug development and market forecasts, with a focus on biologics—an area of shared interest for both pharmaceutical and CDMO companies—alongside the latest topics in pharmaceutical manufacturing.

FREE

Register
C5-02
April 9(Wed.)
11:45-12:30
Ms. Yuko Sekino

Breakthrough from Japanese Research on Learning and Memory: Tackling MCI Treatment with Drebrin Drug Discovery

Ms. Yuko Sekino
President
Institute for Drug Discovery Innovation, NPO


CTO
AlzMed, Inc.


FREE

Register
C5-03
April 9(Wed.)
13:00-13:45
Mr. Keiichi Nakayama

Development of Treatments for Refractory Cancer Using Omics and Data Science

Mr. Keiichi Nakayama
Chief Scientific Officer (CSO)
R&D Department
AntiCancer Technologies, Inc.


We are developing highly scientific evidence-based therapies for refractory cancers (especially pancreatic cancer and small cell lung cancer) with a 5-year survival rate of less than 10%, using omics and data science. In this presentation, I will discuss the basic theory and the current development stage of new therapeutic approaches targeting pancreatic cancer (Pipeline 1: antibodies) and small cell lung cancer (Pipeline 2: small molecule compounds).

FREE

Register
C5-04
April 9(Wed.)
14:15-15:00
Mr. Hideyuki SHIMIZU

Harnessing Information Science to Drive the Future of Drug Discovery

Mr. Hideyuki SHIMIZU
Professo
Institute of Integrated Research, M&D Data Science Center
Institute of Science Tokyo


In this lecture, I will discuss how information science accelerates drug discovery, covering recent advancements from target identification to lead compound acquisition, optimization, and clinical trials. I will then present some of our recent research findings in an omnibus format, highlighting how small molecules, nucleic acids, peptides, and novel modalities are being developed. Finally, I will touch on initiatives aimed at fostering the next generation of drug discovery researchers and developers.

FREE

Register
C5-05
April 9(Wed.)
15:30-16:15
Mr. Atsushi Takano
Mr. Yushi kato

Drug modalities and future outlook of the pharmaceutical market

Mr. Atsushi Takano
Head
Management Consulting
IQVIA Solutions Japan G.K.

 

Mr. Yushi kato
Manager
Management Consulting
IQVIA Solutions Japan G.K.


This session discusses the changes in drug modalities and its impact on the pharmaceuticals market. In addition to small molecule and antibody drugs, new modalities such as nucleic acid drugs, gene therapy, and cell therapy are emerging, and transforming the structure of the market. The impact of these changes on the pharmaceutical market in the future and the intensifying competitive environment due to the diversification of modalities will be discussed in depth.

FREE

Register
C6-01
April 9(Wed.)
10:30-11:15
Mr. Makiya Nishikawa

Challenges and DDS-supported solutions for innovative pharmaceuticals

Mr. Makiya Nishikawa
Professor
Faculty of Pharmaceutical Sciences
 Tokyo University of Science


In recent years, the diversity of drug modalities has led to an acceleration in the development of drugs with significantly different chemical structures and physicochemical properties. This has also led to a variety of formulation-related issues. Drug delivery system (DDS) has attracted attention as a solution to these issues. In this presentation, based on discussions at the APSTJ, the challenges and DDS-supported solutions for innovative pharmaceuticals will be discussed.

FREE

Register
C6-02
April 9(Wed.)
11:45-12:15
Mr. Ryo Suzuki

Research on drug delivery system (DDS) for the brain and their applications in treating brain diseases.

Mr. Ryo Suzuki

Professor

Faculty of Pharmaceutical Sciences

Teikyo University


The transfer of drugs into the brain is strictly limited due to the blood-brain barrier, formed by tight junctions between endothelial cells in the brain's capillaries, leading to delays in developing therapeutic agents for brain diseases. To address this issue, research on drug delivery system (DDS) for the brain has been advancing. In my talk, I would like to introduce DDS into the brain using microbubbles/ultrasound-mediated blood-brain barrier opening, which has gained attention in recent years, and discuss the potential applications of this approach for brain disease treatment.

FREE

Register
C6-03
April 9(Wed.)
13:00-13:30
Mr. Hiroyuki Kusuhara

Prediction of Drug-Drug Interactions: Utilization of Endogenous Biomarkers and Modeling & Simulation

Mr. Hiroyuki Kusuhara
Professor
Graduate School of Pharmaceutical Science
The University of Tokyo


In drug development, assessing the risk of drug-drug interactions (DDIs) involving ADME proteins is crucial to ensuring the safety of co-administered drugs. Among DDI mechanisms, the inhibition of drug transporters responsible for hepatic and renal elimination is particularly significant. Recently, endogenous biomarkers have gained attention as a non-invasive approach to detecting such inhibition in clinical studies without the need for probe drugs. Moreover, biomarker data can be leveraged for quantitative DDI predictions using physiologically based pharmacokinetic (PBPK) modeling. This presentation will focus on clinical data, showcasing case studies on biomarker utilization and its practical applications.

FREE

Register
C6-04
April 9(Wed.)
13:45-14:15
Ms. Yuki Hirai

Latest Advances and Key Insights in Prefilled Syringe Development

Ms. Yuki Hirai
Technical Services Senior Specialist
Pharmaceutical Systems
Nippon Becton Dickinson Company, Ltd.


Prefilled syringe (PFS) formulations are widely used for vaccines and therapeutic drugs including autoimmune diseases, contributing to promoting home treatment and reducing the burden on healthcare workers.

In recent years, the number of PFS formulations has increased. However, with improvements in technologies and the diversifying needs, several evaluations, including compatibility between drug and syringe, usability, and risk management, are getting more necessary than ever before.

This seminar will present the latest developments and key insights into PFS development, based on BD’s extensive expertise.

FREE

Register
C6-05
April 9(Wed.)
14:30-15:30
Mr. Takeshi Tamura

Key points for validation of pharmaceutical packaging (focusing on PTP)

Mr. Takeshi Tamura
board of directors
The Asian Society of Innovative Packaging Technology


Validation, a method for scientifically assuring the quality of pharmaceutical products, is explained from the following perspectives:

- The concept of packaging validation

- The relationship between the function of pharmaceutical packaging and validation

- How to proceed with qualification evaluation

- Types and key points of validation

FREE

Register
C6-07
April 9(Wed.)
16:00-16:30
Mr. Julian Grossmann

Advancements for ATMP Manufacturing

Mr. Julian Grossmann
Sales Manager
Aseptic Technologies
Harro Höfliger Verpackungsmaschinen GmbH


The field of Advanced Therapy Medicinal Products (ATMPs) is at the forefront of modern medicine, offering groundbreaking treatments for a range of diseases, including genetic disorders, cancers, and degenerative conditions.
However, the production of ATMPs presents unique challenges that require novel technologies and innovative solutions to ensure scalability, efficiency, and regulatory compliance where currently used approaches, mostly lab derived, struggle.
The presentation will discuss the latest advancements in closed and automated equipment solutions to support vast ATMP product pipeline and establish manufacturing models for commercial scale.
Discussed technologies are:
Happy Cell Factory - New approach for commercial cGMP manufacturing of Cell & Gene Therapies at scale
baXeptic - From lab to production in aseptic IV bag fill and finish
Leon Nanodrugs - Non-viral vector manufacturing and nano-encapsulation in closed sterile system ready to fill

FREE

Register
C8-03
April 9(Wed.)
13:00-14:45
Simultaneous interpretation
Dr.Gurpreet Singh Sandhu

Sustainability in Healthcare and Pharm

 

*Japanese-English AI real-time translation subtitles available.
Attendees must provide their own smartphones and earphones.

REVA PHARMA

Founder & CEO

Managing Department

Dr.Gurpreet Singh Sandhu


This presentation examines the pharmaceutical industry's environmental challenges, showcasing sustainable practices like energy efficiency and green chemistry through case studies. It explores innovations such as renewable energy systems, addressing regulatory pressures and strategies to overcome challenges. It concludes with future goals and actionable steps.

FREE

Register
4A-01
April 9(Wed.)
10:15-11:00

Total Care and Well-Being Realized through HaaS: A New Challenge for a Sustainable Future


Cancelld

4A-02
April 9(Wed.)
11:20-12:05
Mr. Hiroki Goto

FREE

Register
4A-03
April 9(Wed.)
12:30-13:15
Simultaneous interpretation
Mr. Alan Thomas

IQVIA Japan Pharma Market Insights: Trends in Pharmaceutical Development and Commercialization

Mr. Alan Thomas
Senior Director
Japan Though Leadership
IQVIA Solutions Japan


The pharmaeutical market continues to evolve, with increasing focus on innovation and patient outcomes. This includes a  shift in focus to specialty, biologics, rare disease, CAGT and other emerging areas. Pharmaceutical companies' ability to fully remain "in-house" or "go-it-alone" has become a challenge, with increasing shift in R&D and comercialization - to CDMO , in/out-licensing agreements, and other partnerships. Join IQVIA as we highlight key markets and trends in the developent and commercialization of pharmaceuticals

FREE

Register
4A-04
April 9(Wed.)
13:30-14:15
Mr. Akira Soma

Overcoming Barriers to DX: Streamlining Clinical Development Process through System Integration

Mr. Akira Soma
Solution Director
Oracle Life Sciences
Oracle

 

Chair
Japan CDISC Coordinating Committee


While the significance of Digital Transformation (DX) is acknowledged, many organizations encounter substantial challenges in its execution, often falling short of expected outcomes. This session will explore key barriers that impede DX progress, emphasizing the crucial role of cross-functional collaboration to streamline clinical development processes. It will also present practical case studies of integrating systems such as Study Start Up (SSU), Clinical Trial Management Systems (CTMS), Interactive Response Technology (IRT)/Randomization and Trial Supply Management (RTSM), and Electronic Data Capture (EDC), demonstrating how such integration can streamline and optimize clinical development processes and achieve successful DX.

FREE

Register
4A-06
April 9(Wed.)
15:15-15:45
Mr. Ryota Yamada

Practical Applications of AI Agents in Life Sciences

Mr. Ryota Yamada
CEO
fuku, Inc.


We will present practical applications of Large Language Models (LLMs) and AI agents in life sciences research. From automated analysis of scientific papers and experimental data to streamlining drug discovery processes, we'll showcase successful implementations across research institutions. We'll demonstrate how RAG technology enables utilization of proprietary data, and how autonomous AI agents can execute complex research tasks, leading to significant reductions in R&D timelines and costs.

FREE

Register
4A-07
April 9(Wed.)
16:00-16:45
Mr. Yukihito Iguchi

If you were a DX execution leader, where would you start?

Mr. Yukihito Iguchi
President
Raise Management Company


How should we deploy DX in our organizations?  What is the best way to drive DX?  They would review current complicated business processes, create a DX roadmap that is valuable to customers, and implement it.  The first step in utilizing DX is to increase people's DX literacy while improving processes such as DMAIC* method.  What are Digital Skill Standards, and DX promotion with examples of successes and failures will be presented.
*Define/Measure/Analyze/Improve/Control

FREE

Register
4B-08
April 9(Wed.)
16:00-16:50
Mr. Taro Sekizawa
Kenichi Mori, Ph.D.

The Cutting Edge of Generative AI Utilization in the Pharmaceutical Industry: Challenges and Prospects for Business Transformation

Mr. Taro Sekizawa
Head of Digital Strategy Group
Digital Strategy Planning Department, Digital Transformation Unit Chugai Pharmaceutical Co., Ltd.

 

Kenichi Mori, Ph.D.
Senior Director
DigitalX ResearchX
Astellas Pharma Inc.


As generative AI evolves, bringing new possibilities to the pharmaceutical industry, how can we harness this technology to drive innovation and create value? This session introduces initiatives from participating companies, exploring generative AI's potential for operational efficiency and value creation. We'll discuss challenges and solutions for company-wide implementation, along with prospects for cross-industry collaboration. By sharing insights from industry leaders and engaging in Q&A, we aim to accelerate digital transformation across the pharmaceutical sector. Join us to explore how generative AI is reshaping the future of pharmaceuticals and healthcare innovation.

FREE

Register
4B-01
April 9(Wed.)
10:30-11:15

FREE

Register
4B-02
April 9(Wed.)
11:30-12:00

FREE

Register
4B-03
April 9(Wed.)
12:15-12:45

FREE

Register
4B-04
April 9(Wed.)
13:00-13:30

FREE

Register
4B-05
April 9(Wed.)
13:45-14:15
Mr. Masahiro Terabe
Mr. Toshikazu Kobayashi

Lab DX Trends from a Data Science Perspective

Mr. Masahiro Terabe
PT Digital Technology Professional
Digital Science Gr., Analytical Development Dept.
Chugai Pharmaceutical Co., Ltd.

 

Mr. Toshikazu Kobayashi
Sales Manager
Laboratory solution Pharmaceutical Sales department.
Agilent Technologies Japan, Ltd.


FREE

Register
4B-06
April 9(Wed.)
14:30-15:00

FREE

Register
4B-07
April 9(Wed.)
15:15-15:45
Dr. Shinichiro Fuse

Utilization of AI・Machine Learning Technology in Continuous Flow Synthesis Beyond Labor Reduction

Dr. Shinichiro Fuse
Professor
Graduate School of Pharmaceutical Sciences, Department of Basic Medicinal Sciences, Division of Organic Chemistry,
 Nagoya University



 


Continuous-flow synthesis that uses channels instead of vessels as reactors has garnered much attention in recent years in the production of pharmaceuticals. Efficient identification of the optimal flow reaction conditions using artificial intelligence and machine learning technology has been widely studied in recent years. In this presentation, I would like to introduce the efforts in our group aimed at acquiring valuable chemical and process-related insights beyond just reducing time and labor using machine learning technology in continuous flow synthesis.

FREE

Register
4C-01
April 9(Wed.)
10:30-11:00
Mr. Satoru Hashimoto
MD., PhD. Yoshihiro Motozawa

Digital marketing innovations in the pharmaceutical industry

1. Challenges and Limitations of Existing Marketing Activities from the Perspective of Physicians

2.Breaking away from the current e-marketing practices

Mr. Satoru Hashimoto
CEO and President
TCROSS Co., Ltd.

 

MD., PhD. Yoshihiro Motozawa
Manager
Digital Marketing
TCROSS Co., Ltd.


Inefficient marketing in the pharmaceutical industry is driving up drug prices and negatively impacting the entire healthcare system. InsighTCROSS® leverages data science to reduce unnecessary costs while delivering effective e-marketing strategies. This innovative decision-making support service transforms how the industry approaches marketing. In this presentation, we will explore inefficient marketing from a physician’s perspective and demonstrate how InsighTCROSS® can revolutionize the pharmaceutical industry.

FREE

Register
4C-02
April 9(Wed.)
11:20-11:50
Mr. Atsushi Izutani

Digital marketing around websites for physicians and patients/public

Mr. Atsushi Izutani
Marketing & Value Insight Division
Healthcare Marketing Department Business Design Group
INTAGE Healthcare Inc.


Are you making good use of your company’s website? There are important points of creating a website for doctors, patients, and general consumers. We introduce the following topics.

・Targeting

・Access and search from log data

・Promotion and disease awareness

・Return on investment (ROI) measurement

・Homepage content creation and analysis support

FREE

Register
4C-03
April 9(Wed.)
12:10-12:40
Mr. Rei Araki

Development and In-House Implementation of AI Agents Specialized for Pharmaceutical Companies - Case Studies of Applications from R&D to Sales - 

Mr. Rei Araki
GenerativeX Inc.


This explains approaches for developing AI agents that address pharmaceutical industry-specific regulations and requirements, along with methods for in-house development and operation, featuring examples across a broad value chain from R&D to sales. It covers specific use cases and their effects, including streamlining pharmaceutical research and development, analysis of clinical trial data, support for creating regulatory documentation, and optimization of sales activities.

FREE

Register
4C-04
April 9(Wed.)
13:00-13:30
Mr. Yoshimitsu Imanishi
Mr. Makoto Nakamura

"Patient First” promoted by patient voice and generative AI

Mr. Yoshimitsu Imanishi
EmotionTech, Inc.

 

Mr. Makoto Nakamura
Insmed GK


Insmed, the company in the market to launch new drug for the treatment of pulmonary MAC disease in 2021, is promoting the “Patient First Project. This presentation will introduce the significance of working on “Patient First” with patients' voices as the starting point, advanced activities to analyze patients' voices to discover insights through the use of generative AI, and future prospects.

FREE

Register
4C-05
April 9(Wed.)
13:50-14:20
Mr. Yugo Sasaki

Building relationships with young doctors:

Targeting strategies and approaches required by pharmaceutical companies.

Mr. Yugo Sasaki
CEO
Pharma Information Network Inc.


FREE

Register
4C-06
April 9(Wed.)
14:40-15:10

FREE

Register
4C-07
April 9(Wed.)
15:30-16:00
Mr. Nobuo Miwa

Leveraging doctor-to-doctor platforms: introduction of new information channels in line with the new trends.

Mr. Nobuo Miwa
COO (Chief Operating Officer)
Company Name: Antaa Inc.


For those who are looking for new information dissemination strategies to improve sales of pharmaceutical formulations. This presentation will explain how to effectively deliver information to physicians who are eager to learn by using a SlideShare service where physicians create and share content themselves. We will demonstrate the effectiveness of SlideShare as a quick and easy alternative to webinars and provide specific strategies to meet the needs of physicians with shrinking time.

FREE

Register
4C-08
April 9(Wed.)
16:20-16:50

FREE

Register
4S-03
April 9(Wed.)
11:40-12:00
Mr. Kallis

Driving innovation in drug discovery AI via a Japan-based radiology/pathology image data platform

Mr. Kallis
CEO
Callisto Inc.


FREE

Register
4S-04
April 9(Wed.)
13:00-13:20
Mr. Hajime Kosuge

Introduction to ETQ Reliance®, which leads to the successful digitization of QMS processes

Mr. Hajime Kosuge
Senior Account Manager
Enterprise Division
Hexagon Manufacturing Intelligence Japan (MSC Software Ltd.)


ETQ Reliance is a cloud QMS application that has been adopted by over 100 life science companies globally and over 600 companies in other industries combined. We will be introduced along with practical examples of how many companies have digitized their closed-loop QMS processes from deviations to CAPAs, changes/procedure revisions and training, and audits, all while complying with regulations.

FREE

Register
4S-05
April 9(Wed.)
13:40-14:00
Mr. Ryotaro Ako

Connecting Digitally: A New Approach to Atopic Dermatitis Care – Pioneering with Patient Platforms and Big Data

Mr. Ryotaro Ako
CEO 
Atopiyo LLC


Atopiyo LLC, the operator of the Atopiyo app for atopic dermatitis patients, utilizes 60,000 user-submitted images and 50,000 comments to visualize the timing of medication changes and symptom progression. In collaboration with seven universitiy and national hospitals, the company advances big data analysis using AI-powered image analysis and natural language processing. The app also serves as a disease awareness platform, contributing to better patient education and community engagement. This presentation will discuss various initiatives aimed at improving patient support and care through innovative methods.

FREE

Register
4S-06
April 9(Wed.)
14:20-14:40
Mr. Koki Shimada

What is a Molecular Foundation Model? Development Story and Achievements of the World's Largest AI Model

Mr. Koki Shimada
Representative director CEO
SyntheticGestalt KK


This seminar will introduce SG4D10B, the world's largest molecular-specialized AI developed by SyntheticGestalt. This model revolutionizes drug discovery by utilizing 4-dimensional information based on 10 billion compound data. We will explain the background of the foundation model's development, technical challenges, and differentiation points from other models. We will also share the mechanism that enables high-accuracy predictions with small datasets, achievements in balancing activity, safety, and synthesizability, and present specific applications in the drug discovery process.

FREE

Register
4S-07
April 9(Wed.)
15:00-16:00
Mr. Taisuke Masuda
Mr. Kazuo Nakazato
Mr. Yuto Takemoto

Healthcare venture pitch from Nagoya University

Mr. Taisuke Masuda
CEO
Medridge co.

 

Mr. Kazuo Nakazato
CEO
Head office
BioCMOS Co. Ltd.

 

Mr. Yuto Takemoto
CEO
Quastella Inc.


Medridge co. “Practical application of single cell isolation system and drug discovery support”

Cancer organoids can be grown with high efficiency from patient-derived tumor tissues, potentially enabling patient-specific drug testing and the development of individualized treatment regimens. Circulating tumor cells (CTCs), one of the biomarkers for liquid biopsies, which can be obtained from peripheral blood in a minimally invasive and repeated manner. However, a special method that can detect and collect CTCs is required as there are only a few CTCs among millions of other blood cells. In this lecture, we will introduce a cell isolation system that extracts live CTCs at the single cell level from patient blood and its application to drug discovery support.

 

BioCMOS Co. Ltd. “Environmental and medical application of semiconductor LSI”

R&D has been developed to utilize semiconductor LSIs for environmental and medical applications. BioCMOS Co. Ltd. has brought biomedical biosensor chips to the market, demonstrating 2-dimensional image of biomolecules and bio-interactions, based on the electrochemical detection of potential, current, and impedance. These chips are used as a research tool at several laboratories, although there are several issues to be overcome to be used by medical institutions. Such issues will be discussed, in addition to future prospect to realize ‘chemistry integrated circuit’ where two completely different fields, material chemistry and semiconductor technology, are merged.

Medridge co.  “Practical application of single cell isolation system and drug discovery support”

 

Quastella Inc. “Revolutionizing human-driven evaluation in cell culture!

The AI-powered cell quality evaluation system “Cytometa””

Quastella Inc. provides Cytometa, an AI-based quality evaluation system using cell image analysis. By simply uploading microscope images of MSCs, iPS cells and others, you can easily access analysis reports, including evaluations of growth potential and colony comparison.

Cytometa solves the problems of qualitative evaluation and inter-rater variability, enabling standardized evaluation methods through quantitative analysis.

FREE

Register
C7-04
April 9(Wed.)
13:30-14:30
Simultaneous interpretation
Mr. KAZUYUKI SAWAD

Beyond the Numbers: Japan's Strategic Position in Global API Procurement

 

*Japanese-English AI real-time translation subtitles available.
Attendees must provide their own smartphones and earphones.

 

Mr. KAZUYUKI SAWAD
CEO
SUSUMIRU Consulting Co.,Ltd.

Former Manager,
Purchasing Department,
Sawai Pharmaceutical Co.,Ltd.


Using API-related data including MF registrations, CPHI exhibition data, and generic manufacturers' country of origin disclosures, we will examine Japan's current position and challenges in the global market. Furthermore, we will discuss Japan's unique quality standards and small-volume procurement practices, and propose solutions to achieve true stability in pharmaceutical supply chains.

FREE

Register
C7-02
April 9(Wed.)
10:30-11:30
Mr. Michimasa Koide

Pharmaceutical Laws, Regulations, and Drug Registration Systems in Major ASEAN Countries – Indonesia, Malaysia, Philippines, Singapore, Thailand and Vietnam -

Mr. Michimasa Koide
President and CEO
VPharm Consulting Co., Ltd.


The ASEAN region is poised for growth in the pharmaceutical sector due to rising populations and economic expansion. However, challenges such as complex legal frameworks, underdeveloped pharmaceutical regulations in some areas, and frequent updates to laws and regulations hinder market entry. This presentation provides an overview of pharmaceutical laws, regulations, and drug registration processes in ASEAN countries. It aims to offer valuable insights into regulatory issues and key points to note, supporting companies seeking success in this evolving market as well as to facilitate strategic decision-making for businesses targeting the ASEAN pharmaceutical market by addressing these challenges.

FREE

Register
C7-05
April 9(Wed.)
15:00-17:00

FREE

Register
C8-04
April 9(Wed.)
15:30-16:15
Simultaneous interpretation

Working together to create sustainable supply chains in pharma industry by The Pharmaceutical Supply Chain Initiative (PSCI)

 

*Japanese-English AI real-time translation subtitles available.
Attendees must provide their own smartphones and earphones.


FREE

Register
6K-07
April 10(Thu.)
9:30-11:00
Mr. Yoshihiro MATSUDA
Mr. Hiroshi Ishimaru
Mr. Shuichi Tanabe

Innovative Pharmaceutical Manufacturing Technologies and AI & Machine Learning

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) has developed a guideline on continuous manufacturing (ICH Q13 Guideline), which was officially notified in Japan in 2023. As this guideline also mentions the utilization of models, it is easy to anticipate that AI and machine learning will increasingly be applied to pharmaceutical manufacturing and quality control in the future. In this presentation, I will introduce PMDA's efforts and expectations regarding continuous manufacturing and the application of AI and machine learning from a regulatory science perspective.


Mr. Yoshihiro MATSUDA
Pharmaceuticals and Medical Devices Agency
Principal Senior Scientist for Quality


 

Achieving the Factory of the Future through manufacturing digital transformation

Takeda Pharmaceutical Company is actively promoting manufacturing digital transformation using the data and digital solution to realize the global program “Factory of the Future” in the manufacturing, quality and supply chain division. By sharing best practices across each plants, we aim to maximize the value globally and further improve the efficiency and stability of production and supply. In this session, I will introduce how AI and big data analysis are transforming the pharmaceutical manufacturing at plants.

Mr. Hiroshi Ishimaru
Takeda Pharmaceutical Company Limited



DX Strategies to Accelerate Innovation in CMC Research

The Technology Development of Daiichi Sankyo, aiming to create the future of healthcare through pharmaceutical access transformation, is advancing AI in CPS initiatives to accelerate CMC research DX. This presentation demonstrates our strategy including data/knowledge management, modeling & simulation, robotics implementation, and AI utilization with practical cases, along with our human resource development program.
 

Mr. Shuichi Tanabe
Daiichi Sankyo Co., Ltd.


FREE

Register
6K-08
April 10(Thu.)
11:30-13:00

FREE

Register
6K-09
April 10(Thu.)
13:30-15:30
Simultaneous interpretation

Recent Situation and Challenges in stable supply of Active Pharmaceutical Ingredients


Although stakeholders are increasingly aware of the importance of a stable supply of APIs, several issues in pharmaceutical regulation remain unresolved. This symposium will therefore provide an opportunity to consider current issues and desirable ways forward through presentations and discussions by a representative of generic MAH, an European regulatory affairs consultant and Japanese government officials.

FREE

Register
6K-10
April 10(Thu.)
15:45-16:30
Simultaneous interpretation
Mr. Ian Haydock 

Trends Shaping Global Biopharma R&D In 2024

Mr. Ian Haydock 
Editor-In-Chief, APAC 
Insights
Citeline (a Norstella company)


The global biopharma R&D environment continues to be highly dynamic amid the world's ongoing shift into a post-pandemic environment and all the changes that COVID-19 brought to the sector. This graphical-based presentation will identify and analyse the major trends in global biopharma R&D over the 12-month period ended early 2025, identifying key areas of research, changes in the rankings of major companies and diseases, emerging technologies, rare disease activity and much more. Join for invaluable insights into this key area of activity.

FREE

Register
6A-07
April 10(Thu.)
10:15-11:15
Mr. TAKAHIKO AKIYAMA
Mr. Naoki Nishizawa

【Outreach Program by Japanese Society for Process Chemistry 】

 

1. History of Japanesae Society of Process Chemistry

 

2. Process development of peptide API with novel synthetic strategies.

1. Mr. TAKAHIKO AKIYAMA
 Professor
 Department of Chemistry, Faculty of Science
 Gakushuin University

 

2. Mr. Naoki Nishizawa
 Senior Principal Scientist
 Chemical Research Laboratories
 Nissan Chemical Corporation


1. This process seminar is supported by the Japanse Society for Process Chemistry (JSPC).  JSPC started 25 years ago.  In this lecture, history, current situation, and future of process chemistry of Japan and JSPS.

 

2. The sustainability of peptide manufacturing is challenging in Europe and the US. The environmental impact of liquid-phase synthesis (LPPS) is much lower than that of solid-phase synthesis, but the process development in LPPS is time- and labor-intensive. Our novel and flexible LPPS strategies have greener properties and allow short-term route construction. In this presentation, we will give an overview of the new LPPS method and discuss the sustainability of peptide production.

FREE

Register
6A-08
April 10(Thu.)
11:45-12:30
Dr. Hitoshi Shimizu

The Role of Process Chemistry in New Drug Development

--Innovation all for the patients--

Dr. Hitoshi Shimizu 
Department Manager
Analytical Development Department
Chugai Pharmaceutical Co., Ltd.


The importance of process R&D in pharmaceutical industries remains unchanged during current environmental transformation where the increase of complexity of candidate molecules as well as their competition in the development needs to be welcomed.  The aim of this lecture is to introduce some examples in which process chemistry played a critical role through new drug development.

FREE

Register
6A-09
April 10(Thu.)
13:00-13:45
Mr. Junichi Yasuoka

Key point of highly pure oligonucleotide manufacturing

Mr. Junichi Yasuoka
Group manager
Innovative Pharmaceutical Chemistry Group, Advanced Medical Solutions Research Laboratory
Sumitomo Chemical Co., Ltd.


In recent years, oligonucleotide therapeutics have rapidly expanded, with diverse modalities such as antisense, siRNA, and mRNA advancing in therapeutic applications. Sumitomo Chemical is leveraging its accumulated assets in small molecule API to advance the manufacturing and development of oligonucleotide for therapeutics use. Among these efforts, particular attention has been given to the production of guide RNA for genome editing therapies, which has recently garnered significant attention. This presentation will focus on our initiatives in GMP manufacturing of guide RNA, which is considered chemically challenging to produce.

FREE

Register
6A-10
April 10(Thu.)
14:15-15:00
Mr. Yasufumi Kawanaka

Process Development Strategies, Technology Development Case Studies, and Future Prospects

Mr. Yasufumi Kawanaka
Director, Process Research
CMC & Production HQs
Ono Pharmaceutical Co.Ltd


In recent years, drug candidate compounds have become more diverse and complex, requiring significant time and cost for process development. The development competition is intensifying, and there is a growing demand for increased speed. Pharmaceutical companies need to develop manufacturing processes for active pharmaceutical ingredients (APIs) that overcome the challenges of establishing safe processes, improving productivity, and reducing environmental impact.

Inthis presentation, we will introduce Ono Pharmaceutical's API process development strategy, examples of our technological developments, and our future perspectives.

FREE

Register
6A-11
April 10(Thu.)
15:30-16:15
Mr. Hironao Sajiki

Development of organic synthesis methods using activity control of heterogeneous platinum group catalysts

Mr. Hironao Sajiki
Professor
Applied Chemistry
Aichi Institute of Technology (AIT)

Specially Appointed Professor
Advanced Chemistry (Next-Generation Energy Chemistry)
Gifu Pharmaceutical University


In our laboratory, we have developed heterogeneous platinum group catalysts and applied them to functional group selective catalytic reduction reactions, and we have developed new heterogeneous catalytic reduction catalysts that are functional group selective and applied them to organic synthesis reactions other than catalytic reduction and deuterium labeling reactions. More recently, we have developed research on heterogeneous catalytic reactions that combine new devices and energy, as well as environmentally benign synthetic methods and methods for the production, transportation, and storage of decarbonized fuels. We will present an overview of this work.

FREE

Register
5A-10
April 10(Thu.)
11:45-12:30
Mr. Nobuo Tateishi

Process Validation sturdy for antibody (A-Mab) in compliance with FDA Guidance

Mr. Nobuo Tateishi
Nobbio Consulting LLC


FREE

Register
5A-11
April 10(Thu.)
13:00-13:45
Mr. Taku Nakahara

Development of ulcerative colitis drug using human gut microbiome formulation

Mr. Taku Nakahara
President and CEO
Metagen therapeutics, Inc.


Metagen Therapeutics is a biotech developing innovative medical cares and drugs utilizing human stool-derived gut microbiota. We are currently working on treatments for ulcerative colitis, immuno-oncology, and Parkinson’s disease. This presentation will provide an overview of the development process of the gut microbiota-based therapeutic "MGT-006" for ulcerative colitis, along with evidence of its efficacy and safety demonstrated through clinical trials. Additionally, the latest updates on the establishment of a stool supply chain and interactions with regulatory authorities in various countries will be shared.

 

 

FREE

Register
5A-12
April 10(Thu.)
14:00-14:30
Mr. Hideo Nakata

Ajinomoto Bio-Pharma Services, GeneDesign Efforts Towards Diversifying Nucleic Acid Medicine Modalities

Mr. Hideo Nakata
Group Leader
Business Development
Ajinomoto Bio-Pharma Services,  GeneDesign, Inc.


Nucleic acid medicines are being actively developed worldwide, and as development progresses, their functions and structures are diversifying. At Ajinomoto Bio-Pharma Services, GeneDesign, as an oligonucleotide CDMO, we are undertaking various initiatives to accommodate these diverse modalities. In this seminar, we will introduce some of these efforts, including the synthesis of siRNA and long-chain RNA using enzyme ligation methods, as well as antibody conjugation using AJICAP® technology.

FREE

Register
5A-13
April 10(Thu.)
14:45-15:35

Recent Trends and Future Prospects in CAR-T Development, Manufacturing and Markets

Mr. Satoshi Banba
President
BB-Bridge,Inc.


FREE

Register
5A-14
April 10(Thu.)
15:50-16:35
Mr. Yuki Shioiri
Mr. Yoshitaka Suzawa

Role of instrumental analysis in CMC quality evaluation studies for antibody-drug conjugation (ADC)

Mr. Yuki Shioiri
Senior Researcher
Analytical & Quality Evaluation Reaserch Laboratories Group III, Technology Development Supervisory Department, Technology Division
Daiichi Sankyo Co., Ltd.

 

Mr. Yoshitaka Suzawa
Market Specialist
APAC Technical Specialization and Solution
Agilent Technologies Japan, Ltd.


Antibody-drug conjugate (ADC) is one of the hottest modalities in the pharmaceutical field today. ADCs consist of three components: an antibody delivering the drug to the target site, a small molecule drug as the active agent, and a linker connecting antibody and small molecule. It is essential for CMC quality evaluation research to combine various analytical techniques to accomplish stable supply. This presentation will provide an overview of the analytical evaluation techniques for ADC quality evaluation research and the current status of the analytical instruments used for this purpose. Finally Agilent will introduce the latest application of ADC using HPLC and LC/MS.

FREE

Register
C8-07
April 10(Thu.)
10:15-11:30
Simultaneous interpretation
Muthiah (Mano) Manoharan, Ph.D.
John Desjarlais, Ph.D.

TIDES collaboration project ~International conference on diffusion & peptide therapeutics in CPHI Japan~

1. Advances in Oligonucleotide Therapeutics 

2. Bispecific Antibodies for Oncology and Autoimmune Diseases

 

*Japanese-English AI real-time translation subtitles available.
Attendees must provide their own smartphones and earphones.

Muthiah (Mano) Manoharan, Ph.D.
Senior Vice President of Drug Innovation and Distinguished Research Scientist
Alnylam Pharmaceuticals

 

John Desjarlais, Ph.D.
Chief Scientific Officer,
Xencor, USA


1. This presentation will provide an overview of the latest technologies and developments in the field of oligonucleotide therapeutics. It will also provide an overview of the delivery challenge of oligonucleotide therapeutics and current progress in the field.

 

2. Xencor has created a growing set of bispecific antibodies, using principles of avidity-driven selectivity to improve therapeutic index. Building on these modalities are additional efforts to explore T cell costimulation via signal 2 to potentiate anti-tumor activity of T cells.

FREE

Register
C7-11
April 10(Thu.)
14:15-14:45
 Mr. Daisuke Takagi

Supporting Pharmaceutical Growth: Elixirgen's mRNA Manufacturing Platform

 Mr. Daisuke Takagi
President
Elixirgen Scientific Japan, Inc.


Elixirgen Scientific Japan, with over 600 manufacturing achievements, offers innovative solutions in mRNA production. This presentation highlights our approach to delivering high-quality and flexible services, including purification techniques, process optimization, and scalable solutions from small-scale production to cGMP-compliant clinical manufacturing.

FREE

Register
C7-12
April 10(Thu.)
15:00-15:30
Mr. Yoshihiro Takada

OLIC (Thailand) Limited~from Thailand to the World~One Stop Service CDMO

Mr. Yoshihiro Takada
Managing Director
OLIC (Thailand) Limited


OLIC(Thailand) is the largest CDMO in Southeast Asia. We provide CDMO services from formulation development, clinical trial manufacturing to commercial production. We have more than 30 partners in the world and our products are exported to over 30 countries. Our presentation includes advantages of Thailand, our services, strengths and track record for Japanese pharmaceutical companies.

FREE

Register
C7-13
April 10(Thu.)
15:45-16:15

【SMBC Nikko securities collaboration】 Overview of the CDMO Market

Ms. Shiho Yoshitomi
Solution Consultant、APAC
Evaluate

 

Mr. Jiro Fujiyasu
Director,Head of industorial Research
Industorial Research & Sustainable Solutions Dept.
SMBC NIKKO SECURITIES INC.


FREE

Register
4A-08
April 10(Thu.)
10:15-11:00
Mr. Yoshiyuki Numata

FREE

Register
4A-09
April 10(Thu.)
11:20-12:05
Mr. Takayoshi haraguchi

Enhancing Prescription Growth with Limited Resources: An Omnichannel Strategy Utilizing SaaS and AI

Mr. Takayoshi haraguchi
Executive Officer/VP of Business Development
Shaperon Inc.


This presentation will explain how SaaS and AI can be effectively applied in pharmaceutical commercial operations to:
1. Reduce content creation costs and lead times
2. Expand physician coverage and improve detailing
3. Strengthen compliance with AI-driven solutions

FREE

Register
4A-11
April 10(Thu.)
13:30-14:15
Ms. Jyunko Kimura
Mr. Takashi Hori
Ms. Megumi Araki

Grand Design for MR/Manager Education to Develop Pharmaceutical Specialists
~Vision-driven organizational transformation! Breaking away from education and training that takes the field into consideration~.

Ms. Junko Kimura

Gilead Sciences, Inc.

 

Mr. Takashi Hori

Leap Co.,Ltd

 

Ms. Megumi Araki

Leap Co.,Ltd


In this seminar, we will introduce effective channel utilization strategies to enhance customer engagement, as well as discuss the ideal approach to managing the human capital of sales organizations. We will dive deep into how to intervene based on performance and skill data to improve the current state and generate results. This is a valuable opportunity to explore performance management strategies in business. We look forward to your participation.

FREE

Register
4A-12
April 10(Thu.)
14:30-15:00
Mr. Naohiko Ishiguro
Mr. Yoichiro Nakagawa

DX of product strategies and measures from the patient’s perspective

Mr. Naohiko Ishiguro
Sales Headquarters Medical Sales
 kimura information technology CO., LTD.

 

Mr. Yoichiro Nakagawa
Sales Headquarters Event Sales
kimura information technology CO., LTD.


In order to achieve Patient Centricity, it is essential to gain a full picture of the treatment and understand the insights of doctors and patients.

Patient Journey Visualizer can view electronic medical record data for up to 1000 cases and analyze the background of treatment choices.

TalkAId is a role-play system for MR that utilizes the generative AI and supports skill-improvement through real-world dialogue and feedback.

We will also provide an update of Webinar on the process from hypothesis-making to implementation of a patient-centric product strategy.

FREE

Register
4A-13
April 10(Thu.)
15:15-15:45
Mr. Haruto Shiroma

The Role and Case Studies of Disease Awareness Projectts Based on Health Tech Industry Trends 2025

Mr. Haruto Shiroma
CEO / Founder
Mediwill Inc.


Based on the latest trends in the 2025 health tech and digital health industry, we will explain the role and case studies of disease awareness projects. Specific examples include Asahi Kasei Pharma's "Honeken" project to prevent osteoporosis, Kyowa Kirin's "Kurukotsu Hiroba" project to raise awareness of rare disease, and Medicon's (Becton Dickinson Group) project to raise awareness of inguinal hernia.

FREE

Register
4A-14
April 10(Thu.)
16:00-16:30
Mr. Kazumichi Minato

The Latest Trends and Practical Approaches in SaMD Development and Digital Biomarker Development

Mr. Kazumichi Minato
Representative Director
 CEO
TechDoctor, Inc.


The utilization of new metrics generated from digital data is anticipated in the future development of therapeutic apps and new treatment solutions. In this lecture, we will introduce efforts to develop diagnostic programs, medical devices, and treatment solutions utilizing digital biomarkers as indicators, constructed through the accumulation and analysis of long-term data obtained from general wearable devices such as Fitbit and Apple Watch, and their implementation in society. Additionally, we will discuss the practical hurdles and challenges faced in the development of Software as a Medical Device (SaMD), along with our company's achievements in this area.

FREE

Register
4B-09
April 10(Thu.)
10:30-11:00

FREE

Register
4B-10
April 10(Thu.)
11:15-12:00
Mr. Hiroki Makiguchi

Innovations in Drug Discovery Brought by AI and Supercomputing: The Cutting-Edge Efforts of Tokyo-1

Mr. Hiroki Makiguchi
Chief Thechnology Officer
Xeureka Inc.


FREE

Register
4B-12
April 10(Thu.)
13:00-13:30
Mr. Keishi Akada

FREE

Register
4B-13
April 10(Thu.)
13:45-14:15
Mr. Hiroyoshi Toyoshiba

Drug discovery support solution specialized in hypothesis generation by "AI that discovers the unreported relationship from the existing literature"

Mr. Hiroyoshi Toyoshiba
Executive Officer CTO
FRONTEO, Inc.


KIBIT is an AI excels at discovering hidden relationships not documented in the literature. FRONTEO's AI drug discovery support service, "Drug Discovery AI Factory," utilizes KIBIT to identify highly novel target molecules that could not be found previously, and to propose new indications along with supporting hypotheses. This seminar will feature insights from our algorithm developers, showcasing innovative outputs that enable greater efficiency, accelerated timelines, and improved probability of success in drug discovery.

FREE

Register
4B-14
April 10(Thu.)
14:30-15:00
Mr. Yoshiaki Sakuma

(DRAFT)Paradigm Shift in Research and Development Brought by Technology

Mr. Yoshiaki Sakuma
Director
Health Industries Advisory
PwC Consulting LLC


This presentation explores the future potential for innovation in pharmaceutical industry research and development. We propose an approach to fundamentally reconstruct drug development from the perspective of disruptive innovation, based on viewpoints such as "Redefinition of the Foundation," "Transformation of the Ecosystem," "Development Models," "Infrastructure Revolution," and "Patient-Centric R&D." Through these perspectives, we discuss the evolution and social impact that technology brings to the pharmaceutical industry.

FREE

Register
4B-15
April 10(Thu.)
15:15-15:45
Mr. Tomoya Ookado

The Future Driven by Medical Data: New Developments from Acute Care to Rare Diseases and Oncology

Mr. Tomoya Ookado
Executive Officer, Director
Medical Data Division
TXP Medical Co. Ltd.


This seminar will explore using real-world data (RWD), such as acute care data and electronic medical records, for database research, patient journey mapping, and clinical trial support in acute care, oncology, and rare diseases. Additionally, we will discuss the application of generative AI in healthcare, offering insights into the current state and future outlook of data-driven medicine.

FREE

Register
4B-16
April 10(Thu.)
16:00-16:30
Mr. Takanori Sando
Mr. Takashi Nukaya

PHR Utilization in Drug Development
- Case studies in rare diseases - 

Mr. Takanori Sando
Co-CEO
harmo Co., Ltd.

 

Director
CEO Office
CMIC Holdgings Co., Ltd.

 

Mr. Takashi Nukaya
Corporate Officer
Business Development & Alliance
KNOCK ON THE DOOR Inc


"Evolving PHR accelerates new drug development"
Discover how the epilepsy-focused PHR "nanacara" and the electronic prescription record "harmo" by CMIC Group shape a patient-centered future in clinical development. Through case studies of PHR utilization in clinical trials for refractory epilepsy and patient support models using real-time prescription data, we will delve into how responsive patient support and needs-based insights from PHR can transform and accelerate the path to new therapies.

FREE

Register
4C-09
April 10(Thu.)
10:30-11:00
Mr. Yasuki Kishi

Key Points in Medical AI and Software as a Medical Device (SaMD) Development
Offshore Development of Medical Device Software in Vietnam

Mr. Yasuki Kishi
Vice Director
Global Healthcare Division
FPT Software Japan Co.,Ltd.


FPT Software’s development centers in Ho Chi Minh City and Tokyo have established a system to undertake development for digital health and medical device vendors, with a QMS framework certified under ISO 13485. We provide examples ranging from traditional medical device software to medical AI and cutting-edge SaMD/non-SaMD.

FREE

Register
4C-10
April 10(Thu.)
11:20-11:50
Mr. Adam Sanford

Introducing a New Platform for Drug Discovery Researchers

Mr. Adam Sanford
Director of the Life Sciences Division
CAS

 


CAS, the scientific knowledge management divisions of the American Chemical Society, is expanding its business into the life sciences, building on its track record in data curation and harmonization and in delivering discovery tools and services for researchers. The new CAS BioFinder Discovery Platform™ centralizes experimental data and domain knowledge essential for drug discovery and combines them with predictive capabilities. Authoritative characterization of small molecules and biologics, unambiguous target identification, and normalization of measurement values, assay details, and data sources, enable an informed and accelerated preclinical discovery.

FREE

Register
4C-11
April 10(Thu.)
12:10-12:40
Mr. Yusuke Miyashita

What is an Enablement Platform that Visualizes MR Capabilities and Enhances Activity Quality? 

Mr. Yusuke Miyashita
learning consultant
UMU Technology Japan


Many companies can track increased MR activities through SFA systems, but it's challenging to assess whether these activities' quality has improved and translates into actual performance gains. We introduce a new platform focused on MR enablement. By providing high-quality training opportunities, it visualizes improvements in each MR's capabilities through scoring, supporting enhanced performance. 

FREE

Register
4C-12
April 10(Thu.)
13:00-13:30

FREE

Register
4C-13
April 10(Thu.)
14:00-16:30

FREE

Register
Almost Full
4S-09
April 10(Thu.)
10:20-10:40
Mr. Jin Nakamura

Implementation of Wireless Implantable Brain-Computer Interface and Its Future Prospects

Mr. Jin Nakamura
CEO
HQ
JiMED Inc.


Our company is developing a wireless implantable brain-computer interface (wiBCI) based on research from Osaka University. The wiBCI involves implanting a small EEG device in the skull through surgery, enabling control of devices like PCs with thought alone, and supporting or restoring bodily and communication functions lost due to severe neurological disorders. In this presentation, we will discuss the development status, as well as the database creation of intracranial EEG data and potential applications in bio-sensing devices and new drug development.

FREE

Register
4S-11
April 10(Thu.)
11:40-12:00
Mr. Hidetaka Kai

“Proposal for an ideal preventive environment for the emergence of AD preclinical phase treatment.”

Mr. Hidetaka Kai
Representative Director, President and CEO
MIG Inc.


Several pharmaceutical companies have announced that a treatment for the preclinical stage of Alzheimer's disease will be available in a few years. Identifying people who currently have no subjective symptoms and consider themselves “healthy” during the preclinical phase of the disease is expected to be a very difficult task, as it will require screening many subjects. We will discuss how MIG thinks the AD prevention-treatment environment should be established and aim to realize it.

FREE

Register
4S-12
April 10(Thu.)
13:00-14:30

NEDO Dream Pitch - Pitch by NEDO deep tech start-ups promoting DX to the pharmaceutical industry.

NEDO

AMI Inc.

Cate inc.

Boston Medical Sciences, Inc.


The Open Innovation Venture Creation Council (JOIC), in collaboration with the New Energy and Industrial Technology Development Organisation (NEDO), organises pitch events by start-ups.

This year's event is positioned as a special Dream Pitch, where three start-up companies, each operating under the theme of ‘DX in the pharmaceutical industry’, will introduce their latest technological services

・NEDO

・AMI Inc.“Auscultation DX - Evaluation of cardiac disease by ultra-auscultation during the drug development phase”

・Cate inc.“Research and development of programme medical devices to improve cardiac disease”

・Boston Medical Sciences, Inc. “AI technology for laxative-free endoscopy - the AIM4CRC laxative-free virtual endoscopy system”

FREE

Register
4S-13
April 10(Thu.)
15:00-15:20
Mr. TETSUO FUKUNAGA

Application of cyber-physical systems to business sites

Mr. TETSUO FUKUNAGA
Founder & CEO
FIRST LOOP TECHNOLOGIES, INC.


At our company, we utilize CPS (Cyber-Physical System) to solve on-site issues faced by our customers based on movement data of "people, things, goods (commercial distribution), money, business, energy," etc. We support our customers in promoting their digital business by maximizing investment effectiveness.

In this lecture, we will introduce our company overview, business overview, usage examples, and future development based on our track record in pharmaceutical companies.

FREE

Register
4S-14
April 10(Thu.)
15:40-16:00
Mr. Kentaro Nagata

AI-Powered Planning Optimization: The Future of Pharma Manufacturing

Mr. Kentaro Nagata
CEO
ALGO ARTIS CORPORATION


This session explores how AI drives digital transformation in the pharmaceutical industry, addressing process effi ciency, reducing reliance on individual expertise, and alleviating workloads. Learn actionable insights and real-world examples to revolutionize manufacturing while maintaining safety and quality standards.

FREE

Register
4S-15
April 10(Thu.)
16:20-16:40
Mr. Hidetoshi Hayashi

How to start a manufacturing DX that gets results - with the latest examples of IoT inventory management.

Mr. Hidetoshi Hayashi
 


The need for DX has long been advocated, but full-scale initiatives have yet to be implemented, and there are many misconceptions such as DX = D, X is suddenly a new business, and the cost-effectiveness of DX is calculated in man-days only. The president of the Manufacturing DX Association will talk about the misconceptions and traps to avoid in order to achieve results with DX.

Then, as one concrete example for success, we will tell you about a new method of inventory management using digital technology and case studies from the chemical and pharmaceutical industries on the subject of the Smart Mat Cloud, which uses IoT weighing scales to DX inventory management.

FREE

Register
C1-11
April 10(Thu.)
14:00-14:40
Ms.  Kaoru Majima
Mr. Masahiko Watanabe
Ms. Yumiko Asada

Women in Pharma - Career design for women

Opening panel session: ‘What is the role of women in the pharmaceutical industry?

Ms.  Kaoru Majima

Outside Director

Payroll KK

 

Mr. Masahiko Watanabe

Director

People Services, Global Business Services

AstraZeneca K.K.

 

Ms. Yumiko Asada

Head

People Advisory Group, Global HR

Takeda Pharmaceutical Company Limited


With women playing an increasingly important role in the pharmaceutical industry every year, there is a need for networking opportunities for women beyond company boundaries for the exchange of information. CPHI Women, now in its eighth edition, is a support project to respond to such calls.

 

In the first part of the panel discussion, a moderator with a wealth of experience in human resources in the pharmaceutical and medical device industries will be invited to talk to the two panellists, who are currently working in human resources at pharmaceutical companies, about the current state of women's activities in the pharmaceutical industry.

What has been done in the last five years? What are the recent examples of career paths for women? What systems would you like to introduce in the future...?

To think about my own career in the future. To think about introducing a new system in your company. We look forward to your participation.

FREE

Register
C1-12
April 10(Thu.)
14:50-16:30

Women in Pharma - Career design for women

Group discussion

‘Theme 1: Concerns and challenges in building a career’ and ‘Theme 2: What is a more comfortable working environment - what I am practicing’.

All participants are invited to discuss two themes in a participatory group discussion. As the working environment and working systems in Japan change year by year, the way people build their careers in the future is different. Why not take a fresh look at your own career with people of your own generation and industry, whom you may not have the chance to meet even within the same industry?

Speakers from the opening session in the first part of the conference and guests who have been involved in the pharmaceutical industry for a long time will be invited as facilitators to help you in your discussions.


FREE

Register
6K-12
April 11(Fri.)
9:30-10:30
Simultaneous interpretation
Dr. Osamu Okuda

Drug Discovery and Manufacturing Innovation of Chugai: Strategy and Vision

Dr. Osamu Okuda
Representative Director, President & CEO
Chugai Pharmaceutical Co., Ltd.


Chugai Pharmaceutical, a research-based pharmaceutical company, is approaching its centennial in 2025. With a robust business model based on a strategic alliance with Roche, as its business foundation, Chugai pursues a technology-driven drug discovery approach. In addition to small molecule and antibody drugs, Chugai is also venturing into the new field of mid-size molecule drugs. This presentation will outline Chugai's drug discovery and manufacturing strategies, highlighting key initiatives. Additionally, it will share the company's vision for the future of healthcare, emphasizing co-creation with diverse stakeholders.

FREE

Register
6K-14
April 11(Fri.)
13:00-14:30
Mr. Masaki Mutou

FREE

Register
6K-15
April 11(Fri.)
15:00-15:45
Mr. Toru Fujieda

At the Turning Point of an Era: Challenges and Prospects of CRO Industry

Mr. Toru Fujieda

Chaiman
Japan CRO Association

 

Cousulting and Navigation Unit
CMIC Holdings Co., Ltd.


Drug loss in Japan is a social issue, partly due to Japan losing its appeal as a venue for new drug development amid global trends. CROs are tackling this challenge, aiming to help Japan regain its leadership in drug development. This presentation outlines specific strategies and the future outlook for the CRO industry.

FREE

Register
6K-16
April 11(Fri.)
16:00-16:45
Simultaneous interpretation
Mr. Go Yamamoto

Government Initiatives for Ensuring Thorough Manufacturing and Quality Control of Pharmaceuticals

Mr. Go Yamamoto
Director Office of inspection and Guidance, Director for Counter Narcotics
Compliance and Narcotics Division, Pharmaceutical Safety Bureau
Ministry of Health, Labour and Welfare


FREE

Register
6A-15
April 11(Fri.)
13:00-13:45
Mr. Yuji Morita

Practical Application of Synthetic API PD to Meet the Latest Demands

Mr. Yuji Morita
Manager
API Research Group CMC Laboratories
Mitsubishi Tanabe Pharma Corporation


FREE

Register
6A-16
April 11(Fri.)
14:15-15:00
Mr. Junu Kim

AI-driven pharmaceutical reaction analysis and model-based process design

Mr. Junu Kim
CEO
Auxilart Co., Ltd.


This presentation explores how AI can enhance pharmaceutical reaction analysis and process design. It highlights the development of models for commonly used reactions in drug synthesis, the identification of design spaces, and disturbance analysis for process control applications. The talk also covers a data-driven exploration aimed at automating the extraction of reaction mechanisms from time-series concentration data in chemical reactions, alongside the construction of corresponding physical models. By leveraging digital technologies to reduce experiments, Auxilart aims to contribute to faster and more efficient drug development.

FREE

Register
6A-17
April 11(Fri.)
15:30-16:15
Mr. Takao Saito

Tipping-point to on-demand, decentralized, clone module, and remote continuous manufacturing for pharmaceuticals and fine chemicals

Mr. Takao Saito
CEO
iFactory inc.


On-demand production is changing the traditional production model by offering flexibility, efficiency, immediacy, and cost-effectiveness. This presentation will discuss Japan's progress at this time in the tipping-point to on-demand, decentralized, clone modular facilities, and remote continuous manufacturing for pharmaceuticals and fine chemicals.It will provide a better understanding of what can be done through these types of manufacturing methods in the current dynamic market environment.

FREE

Register
5A-17
April 11(Fri.)
10:30-11:15
Mr. Ichio Shimada

AMED project: Development of RNA-targeted drug discovery technology 

Mr. Ichio Shimada 
JBIC, RIKEN


Interest in RNA that takes three-dimensional structures is growing as a new potential drug targets in pharmaceutical development. However, structural information about RNA, is currently very limited. This presentation provides an overview of structural analysis that combine cryo-electron microscopy, nuclear magnetic resonance, and in silico computational methods to elucidate the three-dimensional structures and dynamic interactions of RNA targets and RNA complexes.

FREE

Register
5A-18
April 11(Fri.)
11:45-12:30

From the Development to Manufacturing, Quality Control, and Quality Assurance of Gene Therapy Products: Challenges and Prospects

Mr. Shin-ichi Fujimura
Manager
Manufacturing Control Department
TAKARA BIO Inc.


Gene therapy products, expected to treat intractable diseases, are increasing in number both domestically and internationally. However, they face many issues before launching, including safety, cost, and regulations. Therefore, it is necessary to establish advanced quality systems and manufacture better products appropriately. Although gene therapy is still in its developmental stages, solving these challenges in the future is expected to benefit more patients. This presentation will explain these challenges and prospects.

FREE

Register
5A-19
April 11(Fri.)
13:00-13:45
Ms. Keiko Suzuki

FREE

Register
5A-21
April 11(Fri.)
14:00-14:30
Mr. KENTARO NAKASE

One-stop-shop service for peptide/protein manufacturing by AJINOMOTO’s unique expression platform technologies CORYNEX®

Mr. KENTARO NAKASE
Manager
Ajinomoto Bio-Pharma Services
AJINOMOTO CO.,INC


CORYNEX® is Ajinomoto Co., Inc.'s proprietary protein secretion production technology using endotoxin-free microorganisms. It excels in producing high-purity, high-accumulation VHH, antibody-like proteins, and long-chain peptides, significantly improving productivity and reducing environmental impact compared to traditional platforms. Additionally, we have developed technology to incorporate non-natural amino acids.
 This presentation will introduce our one-stop-shop service, from strain construction to process development and GMP manufacturing.

FREE

Register
5A-22
April 11(Fri.)
14:45-15:15
Mr. Akio Hayashi

Characterization of mAb therapeutics: required LC/MS system

Mr. Akio Hayashi
LC/MS Application Specialist
TSS, APAC
Agilent Technologies


We will introduce the LC/MS system required for the characterization of mAb therapeutics, consists of 1290 BioLC, 6545XT QTOF-MS, ExD cell, MassHunter BioConfirm software, and the AssayMap Bravo pipetting robot that automates sample preparation.

FREE

Register
5A-23
April 11(Fri.)
15:30-16:15
Mr. Daisuke Fujii

Building a drug discovery ecosystem in Japan through support for startups

Mr. Daisuke Fujii
Director
Office of Pharmaceutical Industry and Venture Support Policy,Policy Planning Division for Pharmaceutical Industry Promotion and Medical Information Management,Health Policy Bureau
Ministry of Health, Labour and Welfare


Ministry of Health, Labour and Welfare (MHLW) is promoting policies to promote medical startups that will play a role in maintaining and improving the health of the Japanese people and raising the level of medical care worldwide, based on the “Startup Development Five-year Plan” and other policies formulated to foster startups through the concerted efforts of the entire government. In this presentation, we will introduce measures to strengthen Japan's drug discovery capabilities, with a focus on measures to support startups and to build a global drug discovery ecosystem.

FREE

Register
C5-17
April 11(Fri.)
13:00-13:45
Mr. Toshio Fujimot

Revitalizing drug discovery ecosystem in Japan ~A new initiative by Ciconia Bioventures

Mr. Toshio Fujimot
Representative Director, Founder and CEO
Ciconia Bioventures Inc.


FREE

Register
C5-18
April 11(Fri.)
14:15-15:00
Mr. Tetsuya Kusakabe

Mr. Tetsuya Kusakabe
General Manager
Department of Innovative Drug Discovery and Development
Japan Agency for Medical Research and Development


FREE

Register
C5-19
April 11(Fri.)
15:30-16:15
Mr. Katsuya Tsuchihara

Seed development and start-up support for academia-originated drug discovery and medical technology by the National Cancer Center

Mr. Katsuya Tsuchihara
Director
Exploratory Oncology Research and Clinical Trial Center/Center for Promotion of Translational Research
National Cancer Center Japan


In recent years, the combination of platform technologies such as antibody drugs and regenerative/cell therapies with multi-omics analysis has been driving the diversification and efficiency of pharmaceutical development. Academia and venture companies are increasingly pursuing open innovation, achieving Proof of Concept (PoC) and aiming to license out to manufacturing and marketing firms. The National Cancer Center is strengthening support for domestic and international researchers and companies, focusing on exit strategies such as "Clinical Marketing" and entrepreneurship support, with the goal of fostering innovation and advancing the commercialization of new technologies.

FREE

Register
C6-15
April 11(Fri.)
10:30-11:00
Mr. Hideo Miura

Recent status and problems of pharmaceutical blister packaging

Mr. Hideo Miura
Chairman
Japan Society of Innovative Packaging Technology


The following will be briefly discussed.
(1) Halogen-containing polymers, which have been widely used, need to be examined in relation to PPWR.
(2) Significance and current status of standardization of PTP dimensions and shape
(3) Status of improvement in usability (ease of opening and prevention of accidental ingestion) due to the aging of the population
(4) Others

FREE

Register
C6-16
April 11(Fri.)
11:45-12:30
Hiroshi Kikuchi, Ph.D.

Importance of DDS technology on the development of nucleic acid medicines and its future view

Hiroshi Kikuchi, Ph.D.
President
DDS Strategy Firm LLC

 

Former Officer
Head of Formulation Strategy
Eisai Co., Ltd.


This presenter started liposomal research for gene therapy in 1994 when he was in Daiichi Pharmaceutical Co., Ltd., and in the field of nucleic acids delivery 26 original scientific papers and 9 basic patents have been published. Thirty years have passed, and APIs have been changed from plasmid DNA to siRNA and mRNA. Lipid nanoparticles (LNP) are necessary for the development of the above nucleic acid medicines. In this presentation the past and the present of LNP research will be introduced, and the future of LNP research including exosome research will be discussed.

FREE

Register
C6-17
April 11(Fri.)
13:00-13:30
Mr. Sven Borc

 100% In-line Content Uniformity and other critical CQA Testing by Q-Control equipment

Mr. Sven Borc
Product Specialist Q-control
Pharma Technology


Increasing demands on quality control in pharmaceutical solid dose production leads to the use of continuous in-line inspection systems.  The CU-120 imspection machine from Pharma Technology is capable to measure up to 120.000 tablets per hour for the following CQA's: mass, dimensions,  API fraction, water content, Content Uniformity, assay and porosity. The machine can be used for product development, process control and supports Real Time Release.

FREE

Register
C6-18
April 11(Fri.)
13:50-14:20
Mr. Tomohiro Asai

Advanced Drug Delivery System for Nucleic Acid and Gene Medicine

Mr. Tomohiro Asai
Professor
School of Pharmaceutical Sciences
University of Shizuoka


Nucleic acids and genes are attracting attention as new drug modalities, and R&D on them is being actively conducted around the world. One of the technologies that holds the key to the success of nucleic acid and gene drug development is drug delivery system (DDS). As DDS technology advances, including lipid nanoparticle (LNP) technology, which has contributed to the practical use of mRNA vaccines, the development of nucleic acid and gene drugs will make great progress. Here, I will provide an overview of recent trends in nucleic acid and gene drug development, focusing on DDS technology. I will also introduce the efforts of the Nucleic Acid and Gene Medicine Focus Group of The Academy of Pharmaceutical Science and Technology, Japan.

FREE

Register
C6-19
April 11(Fri.)
14:40-15:10
English
Mr. Manoj Kumar Pananchukunnath

Drug-Device Combination Products including Biocon’s peptide technology

 

*Japanese-English AI real-time translation subtitles available.
Attendees must provide their own smartphones and earphones.

Mr. Manoj Kumar Pananchukunnath
Chief Scientific Officer
Research and Development

Biocon Ltd.


Drug-device combination products (DDCPs) that involve peptides are gaining prominence in the pharmaceutical and biotechnology sectors due to their potential to enhance drug delivery, improve patient compliance, and enable more effective treatment. They offer innovative solutions for the challenges of peptide delivery, improving both the therapeutic potential of peptides and the overall patient experience. These products typically consist of a drug (the peptide) and a device that aids in the administration or delivery of the drug. Biocon’s involvement in the peptide sector is a part of a broader strategy to make treatments more accessible and affordable while focusing on high-quality standards in the production of peptides and related therapies

FREE

Register
C6-20
April 11(Fri.)
15:30-16:15
Mr. Ryoichi Tanaka

QA department structure and collaboration with CDMOs

Mr. Ryoichi Tanaka
Senior Consultant (Pharmacist)
Consulting Services Division
CM Plus Corporation


In August 2021, the Japanese GMP Ordinance was revised, increasing the requirements for QA work, and the time has come when QA work is dramatically required in terms of both quality and quantity. With the increase in the manufacture of new fields such as biopharmaceuticals, it is necessary for manufacturers to ensure quality throughout the lifecycle and to make continuous improvements through appropriate collaboration with CDMOs, etc., as appropriate, with a focus on QA. This presentation will explain the current QA systems required, including recent case studies.

FREE

Register
C7-15
April 11(Fri.)
10:30-11:15
Mr. Motoyoshi Okamura

Outsourcing in the Development and Manufacturing of New Modalities: Current Status and Future Prospects

Mr. Motoyoshi Okamura
President
Pharmatelier Inc.


Outsourcing of development and manufacturing of biopharmaceuticals has been popular. However, with the emergence of new modalities such as mRNA vaccines and ADCs, CDMOs are increasingly required to provide new manufacturing and quality control services. What will be required of biopharmaceutical CDMOs in the future? The current status of biopharmaceutical CDMOs and the challenges of outsourcing will be outlined.

FREE

Register
C7-17
April 11(Fri.)
13:00-13:30
Mr. Shigetomo Tsujihata

Design of lipid nanoparticles and one-stop CDMO services to expand the potential of mRNA therapeutics.

Mr. Shigetomo Tsujihata
General Manager
Bio Business Div.2nd Dept.
FUJIFILM Toyama Chemical Co., Ltd.


One of the issues to expand the potential of mRNA therapeutics is lipid nanoparticles (LNPs) for mRNA delivery. We have obtained proprietary ionizable lipids through in vivo screening and evaluated their application to LNPs. Some of them showed high activity for RNA delivery and low toxicity, and others have showed potential for extrahepatic delivery.
In this presentation, we will introduce the features and applications of LNPs using our proprietary ionizable lipids and one-stop CDMO services from mRNA to LNPs to meet customers’ needs for mRNA therapeutics.

FREE

Register
C7-18
April 11(Fri.)
13:50-14:20
Mr. Masanori Kataoka

Continuous Manufacturing of Oligonucleotides by “Block-Flow Technology”

Mr. Masanori Kataoka
Chief Executive Officer
Head Office
NATiAS Inc.


Oligonucleotide synthesis via flow chemistry is an ideal method for producing oligonucleotides and can address scalability challenges of conventional solid-phase synthesis. Unfortunately, to date, flow chemistry for nucleotide synthesis has only been applied to synthesize trimer nucleotides, and there is a strong demand to extend the application of flow chemistry to the production of longer oligonucleotide APIs. We have recently succeeded in large scale synthesis of 10-mer phosphoramidites, termed Blockmer™, as raw materials for liquid-phase oligonucleotide synthesis. Using the Blockmer™, we have achieved a one-step elongation to a 24-mer oligonucleotide with in-line deprotection.

In this presentation, we will discuss the details of the oligonucleotide synthesis by flow chemistry in liquid phase using Blockmer™ and our progress toward continuous production of oligonucleotide.

FREE

Register
C7-19
April 11(Fri.)
14:40-15:10
Yusuke Kakizawa

“Empowering Peptide Drug Development: ScinoPharm’s Scalable and Sustainable Approach”

“From Synthesis to Fill-Finish: Tailored Solutions for Complex Peptide Challenges”

Mr. Yusuke Kakizawa
Head of Japan Branch
Japan Branch
ScinoPharm Taiwan


Presentation focuses on ScinoPharm's advanced peptide manufacturing capabilities, highlighting technologies designed to address diverse client development needs while enabling scalable, high-quality production across both drug substances and drug products. ScinoPharm employs robust solutions such as solid-phase peptide synthesis, continuous purification processes, lyophilization, and spray drying for peptide drug substances, as well as fill-finish services in pre-filled syringes/cartridges and in-house assembly for peptide drug products. ScinoPharm is empowered to efficiently and precisely tackle complex manufacturing challenges, advancing cost-effective and environmentally sustainable practices. A snapshot demonstrates why ScinoPharm is a tailored, trusted partner for clients seeking reliable and scalable peptide manufacturing expertise.

FREE

Register
4A-15
April 11(Fri.)
10:15-11:00
Mr. Munenori Senzaki

AI-First Business Transformation in Life Sciences Industry

Mr. Munenori Senzaki
Partner / Healthcare & Life Sciences Industry Leader
IBM Consulting
 IBM Japan


With the evolution of AI and the decline of productive population, more and more companies and organizations are changing their perspective from “adding AI” to “starting with AI”. In this presentation, we will introduce examples of initiatives such as accelerating drug discovery using biomedical foundation model, streamlining clinical trials by incorporating RWD such as electronic medical records and generative AI, turning factories into smart factories using digital technologies, and using generative AI to detect adverse events and support early detection of patients with rare diseases.

FREE

Register
4A-16
April 11(Fri.)
11:20-12:10
Mr. Katsumi Mera
Mr. Yoshihiko Adachi
Mr. Kiyonobu Kawano

FREE

Register
4A-17
April 11(Fri.)
12:30-13:15
Ms. Noriko Yoshikawa

New oppotuinities with with digital health

Ms. Noriko Yoshikawa
coordinator/research fellow
Medical and Engineering Cooperation Coordinator Council
NPO IMEI (Institute for Medical and Engineering Integration)


Digital health will play a major role in future medical care. Artificial intelligence and new modalities are also developing. However, we need a vision of what we can achieve with digital health. First, we will take a bird's-eye view of medical care and consider the healthcare and/or patient journey and digital health. Another important method is the “backcasting approach”, which starts defining a desirable future and works backwards. I will give you tips on how to make digital technology valuable.

FREE

Register
4A-18
April 11(Fri.)
13:30-14:15
Mr. Shigeo Tanaka

FREE

Register
4A-19
April 11(Fri.)
14:30-15:15

FREE

Register
4A-20
April 11(Fri.)
15:30-16:00
Mr. Naoki Kishi

AI for supporting document workflows related to quality assurance

Mr. Naoki Kishi
CEO
EQUES Inc.


In this seminar, we will introduce "QAI," an AI SaaS developed by a startup from the Matsuo Lab at the University of Tokyo, designed to enhance the efficiency of quality assurance operations. We will discuss how AI can be utilized in document creation, review, search, and training, as well as explore the impact of large language models on business processes in the pharmaceutical industry and future developments.

FREE

Register
4A-21
April 11(Fri.)
16:15-16:45
Mr. Yoshiyuki Numata

FREE

Register
4B-17
April 11(Fri.)
10:30-11:00

FREE

Register
4B-18
April 11(Fri.)
11:15-11:45
Mr. Ryo Kitagawa

FREE

Register
4B-19
April 11(Fri.)
12:10-12:55
Mr. Jyunichi Yasumi

Mr. Jyunichi Yasumi
Buisiness Development Division
Hakuhodo Medical


FREE

Register
4B-20
April 11(Fri.)
13:15-13:45
Mr. Kazuaki Hayata

The Future of the Life Sciences with Argentforce

Mr. Kazuaki Hayata
Life Sciences IndustrySolutions, Industry Advisors
Senior Manager
Salesforce Japan Co.,Ltd.


Life Sciences Cloud, designed for the life sciences industry, shows how the combination of data and autonomous AI can shape the future, with a clear demonstration. By bringing together both internal and third-party data in Salesforce and securely connecting it to autonomous AI, this solution allows better data usage in various situations, helping businesses grow.

FREE

Register
4B-21
April 11(Fri.)
14:00-14:30
Mr. Hiroki Yamada
Ms. Ayaka Ito

What Are the New Perspectives in Physician Marketing for Specialty Fields?
— Identifying Core Challenges and Solutions through Collaboration with Specialists —

Mr. Hiroki Yamada
CEO
Medii, Inc.

 

Ms. Ayaka Ito
Pharmaceutical Marketing Department
Medii, Inc.


In specialty fields, including rare diseases and oncology, the low frequency of encounters in clinical settings poses significant diagnostic and treatment challenges for physicians. The traditional push-based information delivery method requires transformation. This seminar will delve into the challenges from a physician's perspective, explore their realities, and highlight Medii's effective initiatives and achievements in addressing these issues.

FREE

Register
4B-22
April 11(Fri.)
14:45-15:15

FREE

Register
4B-23
April 11(Fri.)
15:30-16:00
Mr. Manabu Maekawa

FREE

Register
4B-24
April 11(Fri.)
16:15-16:55

FREE

Register
4C-17
April 11(Fri.)
10:30-11:00
Mr. Syogo Ogawa

Digital content design to enhance product marketing.

Mr. Syogo Ogawa
Account Management Unit
Pharma Information Network Inc.


As physicians' information-gathering trends continue to evolve, effective digital content design has become essential for driving omnichannel marketing. In this seminar, we will revisit the role of digital content in omnichannel marketing and provide concrete insights into key aspects of content planning and creation, including theme setting, expression techniques, and lead flow design.

FREE

Register
4C-18
April 11(Fri.)
11:20-11:50

HCP Customer Engagement Solution for Omni-Channel with Generative AI

Mr. Goro Nishimoto
CEO
LS&HC Data Intelligence and Consulting
DIGITAL TRANSFORMATION and EXPERIENCE inc.


FREE

Register
4C-19
April 11(Fri.)
12:10-12:40

"Keys to Improving Efficiency and Quality in the Healthcare Industry: Learning from AI Utilization Cases in Other Industries"

Ms. Aya Suzuki
Sales headquarters
Unionthink Co., Ltd.


This seminar explores the keys to improving operational efficiency and quality in the healthcare industry by examining successful AI utilization cases from other sectors. We will analyze the transformations AI has brought to various industries and consider how these advancements can be applied to healthcare. This seminar is ideal for those interested in enhancing efficiency and improving quality and services through data utilization. Join us to learn about the latest AI trends and gain practical insights to help solve challenges and drive business improvements in your organization.

FREE

Register
4C-20
April 11(Fri.)
13:00-13:30
Mr. Masaki Nakamura
Mr. Tomoya Ookado

The future of medical data: Creating new value for pharmaceutical companies using Real-World Data.

​​​​​​


The characteristics of RWD (Real World Data) and examples of its use will be presented, explaining how a data-driven approach can bring new value to everything from Research and Development to marketing and patient support. It also examines points to note and future prospects for data utilisation, and explores the possibilities for data-driven healthcare.

FREE

Register
4C-23
April 11(Fri.)
15:15-15:45
Mr. Samon Ashino

Flexibly Adapting to Doctors' Work Style Reform! Enhancing MR Detailing Capabilities with CRM & Data Utilization

Mr. Samon Ashino
Senior Manager
Direction Division
Bigm2y Co., Ltd


It has been a year since the work style reform for doctors began, and the opportunities and time for MRs (Medical Representatives) to meet with doctors have decreased. The era where results could be achieved solely through the efforts of MRs has come to an end, and we are transitioning to an era where digital tools, such as CRM, should be utilized to enhance meeting capabilities. In this seminar, we will re-examine the usefulness of CRM and introduce one of our comprehensive MR support measures: 'a system that integrates internal and external data into CRM and visualizes it in an easy-to-understand manner tailored to the doctors being met with.

FREE

Register
4C-24
April 11(Fri.)
16:00-16:30

FREE

Register
4S-18
April 11(Fri.)
11:40-12:00
Mr. Satoshi Kaneta

AI-Driven Advances in Delirium prediction

Mr. Satoshi Kaneta
CEO
DELISPECT Inc.


Delirium is a consciousness disorder that frequently occurs in the elderly. It can lead to a decline in patients' physical and cognitive functions, increase the risk of dementia, and impose a greater workload on healthcare professionals. Additionally, it contributes to prolonged hospital stays and rising medical costs. Amid these challenges, advancements in AI technology have recently led to the emergence of innovative delirium prediction methods worldwide. This lecture will provide an overview of the latest trends in AI-driven delirium management.

FREE

Register
4S-19
April 11(Fri.)
13:40-14:00
Mr. Hiroki Kiuchi

Exploring New Business Opportunities in the Healthtech Sector: The Forefront of AI Utilization

Mr. Hiroki Kiuchi
CEO
iFlasco inc.


The use of AI is inevitable in innovations in the health tech sector, such as medical DX, wearable devices and digital therapies, and the key is how effectively we leverage the information from precedent case studies. In this presentation, multiple sources of information, including media and reports, will be collected and analyzed across the board to explore specific actions that will lead directly to new businesses, including precedent cases and discovery of potential needs.

FREE

Register
C5-15
April 11(Fri.)
10:30-11:15
Mr. Hiroshi Urayama

Achieving stable supply of pharmaceutical raw materials through supply chain visualization

Mr. Hiroshi Urayama
Department Manager
Business Development Department
Resilire Inc.


Currently, the drug shortage continues , and one of the reasons for this is the increasing complexity of the supply chain. Pharmaceutical companies continue to increase the number of products , and are switching to outsourced manufacturing. “Resilire” is a cloud system that visualizes the supply chain and makes supply chain management operations more efficient. It is used by over 30 pharmaceutical companies, supporting their stable supply.

FREE

Register
C5-16
April 11(Fri.)
11:45-12:30
Simultaneous interpretation
Mr. Tadao Takano

Establishing a supply chain structure based on CDMOs for entering the Japanese market

 

*Japanese-English AI real-time translation subtitles available.
Attendees must provide their own smartphones and earphones.

Mr. Tadao Takano

CEO / President of Bushu Pharmaceuticals Ltd.


FREE

Register
6A-00
April 11(Fri.)
12:00-12:30

Updated status of the Self-imposed Standard of GMP for Pharmaceutical Excipients

Mr. Kozo Kishi
General Manager
Quality Assurance
Daido chemical Corporation


“The Self-imposed Standard of GMP for Pharmaceutical Excipients” was developed by IPEC Japan in 2016. After that、data integrity and other items have become necessary for GMP management of pharmaceutical excipients, and ”The Joint IPEC-PQG Good Manufacturing Practice Guide for Excipients” developed by IPEC Federation was revised in 2022. Now we are currently working on revising “The Self-imposed Standard of GMP for Pharmaceutical Excipients” based on this guide to incorporate the above. We will introduce some of the contents of the revision.

FREE

Register
6C-15
April 11(Fri.)
11:00-11:45
Simultaneous interpretation
Mr. KAZUYUKI SAWADA

Unlocking New Opportunities in API Procurement:

Building relationships with leading manufacturers, particularly in India, China and other countries

 

*Japanese-English AI real-time translation subtitles available.
Attendees must provide their own smartphones and earphones.

Mr. KAZUYUKI SAWADA
CEO
SUSUMIRU Consulting Co.,Ltd.

 

Former Manager
Purchasing Department
Sawai Pharmaceutical Co.,Ltd.


Drawing on 17 years of API procurement experience, this presentation offers practical approaches for pharmaceutical buyers and trading companies to effectively utilize expos in building partnerships with key manufacturers. We will explore specific methods for relationship building through expo communications, with special focus on crucial elements for successful collaboration with Indian and Chinese manufacturers.

FREE

Register
6C-16
April 11(Fri.)
13:00-13:30

Enhancing Client Partnerships: Success Stories in Small Molecule CDMO Collaborations

 

*Japanese-English AI real-time translation subtitles available.
Attendees must provide their own smartphones and earphones.

PharmaBlock Sciences (Nanjing), Inc. 


FREE

Register

 

You can apply for multiple seminars at once.

For seminars where pre-registration has closed, you may still be able to attend on the day if there are available seats. Please check the seminar venue about 10 minutes before the start time.
To apply for a seminar, you will need the ID issued upon completing the 'Pre-Registration.' If you have not registered yet, please complete the Pre-Registration first.
Recommended browser is Google Chrome.
Page Top
Loading...